<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080275</url>
  </required_header>
  <id_info>
    <org_study_id>019-02-03-CR</org_study_id>
    <secondary_id>OCEANS</secondary_id>
    <nct_id>NCT00080275</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety &amp; Efficacy of a Combination of Niacin ER &amp; Simvastatin in Patients With Dyslipidemia (OCEANS)</brief_title>
  <official_title>An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kos Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kos Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this 24 week study is to compare the effectiveness and safety of different
      doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood
      (dyslipidemia).

      At least 600 subjects with a similar medical condition will take part in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      To evaluate the safety and efficacy of the combination product niacin ER and simvastatin (NS)
      in patients with primary type II dyslipidemia and to descriptively compare flushing rates
      between two Titration Schedules for NS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>600</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin Extended-Release and simvastatin Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has primary Type II hyperlipidemia or mixed dyslipidemia.

          -  If the patient is currently taking a lipid modifying medication other than Zocor &amp;
             he/she is willing to discontinue this medication

          -  LDL-C levels and/or non HDL-C levels above normal.

          -  Reasonable compliance with a standard cholesterol-lowering diet for a minimum of 4
             weeks prior to screening and for the duration of the study.

        Exclusion Criteria:

          -  Patient has an allergy, hypersensitivity, or intolerance to niacin, statins, or their
             derivatives.

          -  HbA1c â‰¥ 9% in diabetic patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2004</study_first_submitted>
  <study_first_submitted_qc>March 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2004</study_first_posted>
  <last_update_submitted>October 31, 2006</last_update_submitted>
  <last_update_submitted_qc>October 31, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2006</last_update_posted>
  <keyword>Niacin</keyword>
  <keyword>Statin</keyword>
  <keyword>Zocor</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Stroke</keyword>
  <keyword>High-Density Lipoprotein Cholesterol</keyword>
  <keyword>Low-Density Lipoprotein Cholesterol</keyword>
  <keyword>Lipoprotein</keyword>
  <keyword>Lipid</keyword>
  <keyword>Niacin ER/simvastatin</keyword>
  <keyword>Total Cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

